By Drug Class / Mechanism

Glycopeptides & Lipopeptides Market Analysis

Cross-industry research covering Glycopeptides & Lipopeptides across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering Glycopeptides & Lipopeptides

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Pharmaceuticals·Market: USD 25.3 Billion (2025)·CAGR: 6.4%

Vancomycin LOE has structurally eroded branded revenue; generic and biosimilar-adjacent formulations now dominate GPO contracting. Daptomycin maintains a residual branded premium in MRSA bacteremia, but net price compression through PBM and GPO rebate channels has reduced effective realization to WAC minus 35–45% (Claritas model).

12%

Market Share

4.8%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments